PLA2G7 and chronic obstructive pulmonary disease: Regarding the glucocorticoid class specifically, it is known that short-term oral prednisone (4 days, 30 mg/day) produces a distinct blood gene expression signature in COPD patients and that neither PLAC8 nor PLA2G7 were differentially expressed when comparing pre-treatment patients to day 4 of treatment [48].